Prognostic Value of Biochemical Response to Neoadjuvant Androgen Deprivation before External Beam Radiotherapy for Prostate Cancer: A Systematic Review of the Literature

• Published in: Cancer treatment reviews Vol. 46; pp. 35 - 41
• Main Authors: Zilli, Thomas, Dal Pra, Alan, Kountouri, Melpomeni, Miralbell, Raymond
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.05.2016
• Subjects: Androgen Antagonists - therapeutic use; Androgen deprivation; Animals; Biochemical response; Clinical Trials, Phase III as Topic; Hematology, Oncology and Palliative Medicine; Humans; Kallikreins - metabolism; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prognosis; Prostate cancer; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - radiotherapy; Prostatic Neoplasms - therapy; PSA; Radiotherapy; Randomized Controlled Trials as Topic; Prostate Cancer; Radiotherapy; Androgen deprivation; Biochemical response; PSA; Prostate cancer
• ISSN: 0305-7372; 1532-1967
• DOI: 10.1016/j.ctrv.2016.03.016

Highlights • In patients with intermediate- or high-risk localized prostate cancer treated with curative radiotherapy biochemical response to neoadjuvant androgen deprivation represents a strong predictor of improved outcome. • PSA decline during the first months of androgen blockade may represent a simple and robust surrogate marker of the intrinsic androgen sensitivity of tumor cells. • A therapeutic gain would be possible by individualizing treatment strategies based on the PSA response after neoadjuvant androgen deprivation.